Top

Published in:

01-09-2010

Pregnancy after prophylactic total gastrectomy

Authors: Pardeep Kaurah, Rebecca Fitzgerald, Sarah Dwerryhouse, David G. Huntsman

Published in: Familial Cancer | Issue 3/2010

Abstract

Hereditary diffuse gastric cancer is an autosomal dominant inherited cancer predisposition syndrome characterized by susceptibility to diffuse gastric and lobular breast cancers. Since current screening options for diffuse gastric cancer are ineffective, prophylactic total gastrectomy (PTG) is a recommended option for unaffected germline CDH1 mutation carriers. It is unknown whether pregnancy after surgery is possible or advisable due to potential maternal nutritional deficiencies. In this report we describe the pregnancy outcomes in three CDH1 mutation positive women after PTG and in a CDH1 mutation negative woman after total gastrectomy for early gastric cancer.

Caldas C, Carneiro F, Lynch HT et al (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880PubMed

Kaurah P, MacMillan A, Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with Hereditary Diffuse Gastric Cancer. JAMA 297:2360–2372CrossRefPubMed

Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405CrossRefPubMed

Shaw D, Blair V, Framp A et al (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 54:461–468CrossRefPubMed

Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. N Engl J Med 344:1904–1909CrossRefPubMed

Norton JA, Ham CM, Dam JV et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879CrossRefPubMed

Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687CrossRefPubMed

Suriano G, Yew S, Ferreira P et al (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 11:5401–5409CrossRefPubMed

Lewis FR, Mellinger JD, Hayashi A et al (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130:612–617 discussion 617-619CrossRefPubMed

10.

Chun YS, Lindor NM, Smyrk TC et al (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92:181–187CrossRefPubMed

11.

Peck DA, Welch JS, Waugh JM et al (1964) Pregnancy following gastric resection. Am J Obstet Gynecol 90:517–520PubMed

12.

Pisani BJ (1958) Term gestation following total gastrectomy. J Am Geriatr Soc 6:99–102PubMed

13.

Kushner R (2000) Managing the obese patient after bariatric surgery: a case report of severe malnutrition and review of the literature. JPEN J Parenter Enteral Nutri 24:126–132CrossRef

14.

Dao T, Kuhn J, Ehmer D et al (2006) Pregnancy outcomes after gastric-bypass surgery. Am J Surg 192:762–766CrossRefPubMed

15.

Karmon A, Sheiner E (2008) Pregnancy after bariatric surgery: a comprehensive review. Arch Gynecol Obstet 27:381–388CrossRef

16.

Patel JA, Colella JJ, Esaka E et al (2007) Improvement in infertility and pregnancy outcomes after weight loss surgery. Med Clin North Am 91:515–528 xiiiCrossRefPubMed

17.

Patel JA, Patel NA, Thomas RL et al (2008) Pregnancy outcomes after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 4:39–45CrossRefPubMed

Title: Pregnancy after prophylactic total gastrectomy
Authors: Pardeep Kaurah
Rebecca Fitzgerald
Sarah Dwerryhouse
David G. Huntsman
Publication date: 01-09-2010
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-009-9316-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Differences in clinical and pathological characteristics of colorectal cancer in Arab as compared to Jewish patients in Northern Israel

Screening for germline DND1 mutations in testicular cancer patients

Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma

Carney triad versus Carney Stratakis syndrome: two cases which illustrate the difficulty in distinguishing between these conditions in individual patients

Atypical identification of Lynch syndrome by immunohistochemistry and microsatellite instability analysis on jejunal adenocarcinoma

Identification of the first case of germline duplication of BRCA1 exon 13 in an Italian family

Keynote webinar | Spotlight on antibody–drug conjugates in cancer